RT Journal Article
T1 Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER.
A1 Bethencourt-Baute, Juan Jose
A1 Sanchez-Piedra, Carlos
A1 Ruiz-Montesinos, Dolores
A1 Medrano-San-Ildefonso, Marta
A1 Rodriguez-Lozano, Carlos
A1 Perez-Pampin, Eva
A1 Ortiz, Ana
A1 Manrique, Sara
A1 Rosello, Rosa
A1 Hernandez, Victoria
A1 Campos, Cristina
A1 Sellas, Agusti
A1 Sifuentes-Giraldo, Walter Alberto
A1 Garcia-Gonzalez, Javier
A1 Sanchez-Alonso, Fernando
A1 Diaz-Gonzalez, Federico
A1 Gomez-Reino, Juan Jesus
A1 Bustabad-Reyes, Sagrario
K1 Biologic treatment
K1 Clinical practice
K1 Juvenile idiopathic arthritis
K1 Safety therapy
AB Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood. All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates. A total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years. Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs 7.9%, p  Survival and suspension by remission of biologics were higher when these compounds were initiated in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection was observed in patients under 16 years old.
PB BioMed Central
YR 2018
FD 2018-10-10
LK http://hdl.handle.net/10668/13057
UL http://hdl.handle.net/10668/13057
LA en
NO Bethencourt Baute JJ, Sanchez-Piedra C, Ruiz-Montesinos D, Medrano San Ildefonso M, Rodriguez-Lozano C, Perez-Pampin E, et al. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER. Arthritis Res Ther. 2018 Oct 10;20(1):227
NO BIOBADASER is supported by the Research Unit of the Spanish Society ofRheumatology (FER) and the Spanish Agency for Medicines and MedicalDevices (AEMyPS). Grants in approximately equal amounts were received fromBiogen, Bristol-Myers Squibb, Pfizer, Roche, Samsung Bioepis, Lilly, Regeneron,Novartis, Janssen, Celgene, and MSD. These pharmaceutical companies had norole in this study. All researchers in this work are independent from the funders.In the collaboration contracts signed by the Spanish Society of Rheumatology, independence of the BIOBADASER registry has been affirmed with respect tothe analyses as well as the diffusion of data and results.
DS RISalud
RD Apr 17, 2025